NCT07605390Enrolling by invitation
RAndomized EHR-based Prescribing to Improve Disease-modifying Therapies for Cardio-Kidney-Metabolic Care (RAPID-CKM)
RAPID-CKM: RAndomized EHR-based Prescribing to Improve Disease-modifying Therapies for Cardio-Kidney-Metabolic Care.
Source: ClinicalTrials.gov · Last updated 15 Oct 2026
Brief summary (registry, in English)
The goal of this pragmatic randomized clinical trial is to determine whether an Epic-based clinician notification increases initiation of guideline-directed cardio-kidney-metabolic (CKM) therapies in adults with type 2 diabetes and confirmed albuminuria. The main question it aims to answer is: • Does an Epic clinician notification improve initiation of guideline-directed CKM therapies compared with usual care? Researchers will compare an Epic in-basket clinician notification strategy with usual care. In the intervention arm, the treating clinician will receive an Epic notification identifying confirmed albuminuria and potential eligibility for guideline-directed CKM therapies using existing electronic health record (EHR) data. Participants in the usual care arm will receive standard clinical care without notification.
- Status (registry)
- Enrolling by invitation
- Study type
- Interventional
- Enrollment
- 600 (estimated)
- First submitted
- 19 May 2026
- Start date
- 6 Aug 2026
- Primary completion date
- Jan 2028
- Lead sponsor
- Baylor Research Institute
- Diseases
- Chronic kidney disease, Type 2 diabetes
- NCT number
- NCT07605390
What you commit to
- Study type: Interventional
- Planned participants: 600
- From 6 Aug 2026 to the primary completion date, Jan 2028
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Contraindication or documented intolerance to all eligible guideline-directed CKM therapies
- Contraindicated drug interactions (e.g., strong CYP3A inhibitors with finerenone)
- Other guideline- or labeling-based contraindications to therapy initiation
Other illness
- Type 1 diabetes mellitus
Lab values
- Hyperkalemia or elevated baseline serum potassium precluding safe therapy initiation
Other
- Advanced kidney dysfunction below recommended initiation thresholds for SGLT2i or finerenone
Who the study is looking for
- Adults aged ≥18 years
- Diagnosis of type 2 diabetes mellitus
- Receiving outpatient care within Baylor Scott \& White Health
- At least 1 outpatient encounter within the preceding 12 months
- Confirmed albuminuria (UACR \>30 mg/g)
- Eligible for one or more guideline-directed CKM therapies based on - prespecified clinical criteria and EHR review
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Baylor Scott and White Health Coordinator of this site? Confirm its status | Dallas | United States | Unknown status |
| Baylor Scott and White, Advanced Heart Care Coordinator of this site? Confirm its status | Plano | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.